AvenCell Therapeutics Doses First Patient in Phase I Trial of Dual-Targeting CAR-T AVC-203
AvenCell Therapeutics has dosed the first patient in its Phase I QUADvance trial testing AVC-203, a CRISPR-engineered allogeneic CAR-T therapy targeting CD19 and CD20 in relapsed or refractory B-cell malignancies.